Non-small cell lung cancer · line 1 · Osimertinib + pemetrexed + carboplatin/cisplatin (FLAURA-2 regimen, EGFR-mut NSCLC, 1L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-OSI-PEM-PLATINUM-NSCLC |
| ID | IND-NSCLC-EGFR-1L-OSI-CHEMO |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-FLAURA-2-PLANCHARD-2023 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L for EGFR-mutated metastatic NSCLC (ex19del or L858R) based on FLAURA-2 (Planchard NEJM 2023). PFS HR 0.62 vs osi monotherapy; CNS PFS HR 0.40. NCCN cat 1 alternative-preferred 1L. Reuses REG-OSI-PEM-PLATINUM-NSCLC (4 cycles induction → osi+pem maintenance). Sister indication IND-NSCLC-EGFR-MUT-MET-1L (osi monotherapy / FLAURA) is the standard-track choice for lower-risk presentations. Sequenced to IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ on progression. OS data immature at FLAURA-2 primary analysis — reassess threshold for osi+chemo vs osi mono when mature OS reads out.
Used By
No reverse references found in the YAML corpus.